ICBI UPDATE ON THE ROAD TO THE CURE - Moving Forward to Eradicate Parkinson’s · Parkinson's Resource Organization

ICBI UPDATE ON THE ROAD TO THE CURE - Moving Forward to Eradicate Parkinson’s

Category: Road to the Cure

Approval of 5th Patent - ICB International, Inc., (“ICBII”), was notified on August 15, 2018, by the European Patent Office that Company’s 5th patent was approved and will be published online in 2-3 months. ICBII management is indeed happy about the progress in building a robust IP (Intellectual Property) portfolio to protect its therapeutic drugs upon approval by the FDA for the treatment of Alzheimer’s and Parkinson’s diseases in the USA and Europe.

The Company has several pending US and European patents at different stages of prosecution. Patent prosecution, particularly in the USA, is very expensive. The Company has spent more than $600K in prosecuting five patents, which is ~12% of all the funds ICBII has raised so far.

Status of Cloning of SMART Molecule (SM) for Parkinson’s Therapy

ICBII has cloned one segment of the alpha-synuclein-SM, a potential drug for modifying Parkinson’s disease. The scientists are now busy in evaluating if this cloned segment has the desired characteristics of SM. Science uses transgenic mice in the evaluation of the cloned SM, but before testing, the mice must grow to a certain age. We will keep you posted on the progress.

ICBII Seeking Funds Development of LRRK2-SM for Parkinson’s Therapy

About 160 individuals per 100 000 people 65 years or older are diagnosed with Parkinson's disease in the USA each year, with similar incidence estimates in other high-income countries. This incidence makes Parkinson's disease the second most common neurodegenerative disorder after Alzheimer's disease. A Review in The Lancet Neurology [Volume 15, ISSUE 12, P1257-1272, November 01, 2016] covers the epidemiology and most recent evidence on environmental factors that can affect the risk of Parkinson's disease, from pesticide exposure (which increases risk) to caffeine consumption (which might reduce it). Knowledge about manageable risk factors is essential to design primary prevention interventions that could delay disease onset. However, the cause of Parkinson's disease is multifactorial. Even though only about 10% of patients report a positive family history, at least 30% of the risk of developing this movement disorder (an underestimation, according to many geneticists) can be, or are, directly attributed to genetic factors; therefore, understanding disease genetics is key to deciphering the complex pathogenesis of Parkinson's disease and find therapeutic targets for disease-modifying drugs.

Mutations in Leucine-rich repeat kinase 2 (LRRK2) have been identified as a genetic cause of familial Parkinson’s disease (PD) and have also been found in the more common sporadic form of PD, thus positioning LRRK2 as important in the pathogenesis of PD. Although science has identified more than 20 mutations, the LRRK2 mutation Gly2019Ser is the most common genetic cause of Parkinson's disease worldwide. This mutation has the highest frequency (20%) in Ashkenazi Jewish and Arab-Berber populations.

More investigation is needed to understand the exact mechanism by which mutant LRRK2 causes neuron death. However, the mice overexpressing mutant LRRK2 exhibit long-term lipopolysaccharide-induced neuronal loss, which is accompanied by an exacerbated neuroinflammation in the brain, thereby providing mutant LRRK2 as an important therapeutic target for interfering with the onset and progression of PD.

ICBII has embarked on a program to develop inhibitors of mutant LRRK2 by developing mLRRK2-SM. People often wonder why the cost of developing drugs is so high. An example might be in the following. The cost of mLRRK2 is about $10,000 per mg, and the Company must buy at least 50 mg of the protein to start the project.

WOULD YOU LIKE TO HELP get these drugs to market faster? The joy of being a part of this historical event can be had by helping ICBI find the funds to bring these trials to fruition through your investing, including your IRA, and by finding others with the financial ability and humanitarian mindset to accomplish the - until now - impossible. Please contact Jo Rosen at Parkinson’s Resource Organization 760-773-5628 or jorosen@Parkinsonsresource.org or by contacting ICBI directly through their website http://icbii.com/ or by phone 858-455-9880.

IMAGINE the world without Parkinson’s, MSA or Alzheimer’s disease. JUST IMAGINE.

Share This Article:

Google+

Contact Us

Physical Address
Parkinson's Resource Organization
74090 El Paseo #104
Palm Desert, CA 92260

Local Phone
(760) 773-5628

Toll-Free Phone
(877) 775-4111

General Information
info@parkinsonsresource.org

 

Like! Subscribe! Share!

Did you know that you can communicate with us through Facebook, Twitter, LinkedIn, YouTube, and now Instagram?

PRIVACY POLICY TEXT

 

Updated: August 16, 2017